Personalis is a company that is transforming the active management of cancer through breakthrough personalized testing. The company aims to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Personalis' highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. The company's products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California.